Roivant and Arbutus have a month to decide if they're going to set up a new company for RNA delivery.

A Celgene spinout known as Celularity with some of the biggest names in biotech and Silicon Valley has raised $250 million for its work in cancer.

The Swiss biotech penned a CHF 127.5 million ($138 million) deal for the human neutrophil elastase inhibitor to expand its clinical pipeline.

The biotech is adding 510 patients to the phase 3 aducanumab trials after seeing more “variability” than expected in a sample size re-estimation.

Aradigm's CEO, chief medical officer and chief financial officer resigned.

UCLA scientists invented a gene-synthesis technology that allows scientists anywhere to make their own genes quickly and efficiently.

Astellas has bought out a U.S. biotech that wants to ensure cell therapy products aren’t rejected by a patient’s immune system.

Bristol-Myers is committing $3.6 billion to a deal that gives Nektar most of the profits and freedom to develop the drug in other combinations.